EADV 2018: Tildrakizumab Maintains PASI 75 in Patients With Moderate to Severe Psoriasis
PASI 75 responses were maintained for 3 years by patients who had responded to the drug at week 28.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.